Clotting Propensity of Surface-Treated Membranes in a Hemodialysis Set-up That Avoids Systemic Anticoagulation

Hideki Kawanishi; Masahide Koremoto; Casper F M Franssen; Marco van Londen

doi:10.1016/j.semnephrol.2023.151482

Clotting Propensity of Surface-Treated Membranes in a Hemodialysis Set-up That Avoids Systemic Anticoagulation

Semin Nephrol. 2024 Jan 22:151482. doi: 10.1016/j.semnephrol.2023.151482. Online ahead of print.

Authors

Hideki Kawanishi¹, Masahide Koremoto², Casper F M Franssen³, Marco van Londen⁴

Affiliations

¹ Tsuchiya General Hospital, Hiroshima, Japan.
² Asahi Kasei Medical Co., Ltd., Tokyo, Japan.
³ Department of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands. Electronic address: c.f.m.fransen@umcg.nl.
⁴ Department of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands.

PMID: 38262850
DOI: 10.1016/j.semnephrol.2023.151482

Abstract

The development of biocompatible membranes, aiming to limit the inflammatory response, oxidative stress, and coagulability during hemodialysis, has been an important step in reducing dialysis-related adverse outcomes. This includes a reduction in the risk of clotting of the extracorporeal circuit, thus enabling hemodialysis with a reduced dose or even without systemic anticoagulant drugs in patients with an increased bleeding risk. In this article, we summarize the in vitro research and clinical evidence on the antithrombotic properties of vitamin E- and heparin-coated membranes.

Keywords: Anticoagulation; dialyzer; hemodialysis; heparin-coated; membrane; vitamin E-coated.

Publication types

Review